I-Tech AB (ITECH.ST)
SEK 79.8
(0.0%)
SEK 79.8
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.28 Million SEK | 77.37% |
| 2022 | 2.41 Million SEK | -27.82% |
| 2021 | 3.34 Million SEK | -21.86% |
| 2020 | 4.27 Million SEK | 238.18% |
| 2019 | 1.26 Million SEK | 317.49% |
| 2018 | 303 Thousand SEK | -50.57% |
| 2017 | 613 Thousand SEK | -83.15% |
| 2016 | 3.63 Million SEK | 2479.43% |
| 2015 | 141 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 5.68 Million SEK | 71.81% |
| 2024 Q1 | 3.53 Million SEK | -17.34% |
| 2024 Q2 | 3.3 Million SEK | -6.56% |
| 2023 Q4 | 4.28 Million SEK | -1.83% |
| 2023 FY | 4.28 Million SEK | 77.37% |
| 2023 Q1 | 2.34 Million SEK | -3.03% |
| 2023 Q2 | 2.28 Million SEK | -2.48% |
| 2023 Q3 | 4.36 Million SEK | 91.06% |
| 2022 Q4 | 2.41 Million SEK | -43.88% |
| 2022 FY | 2.41 Million SEK | -27.82% |
| 2022 Q1 | 2.41 Million SEK | -27.67% |
| 2022 Q2 | 4.46 Million SEK | 84.66% |
| 2022 Q3 | 4.3 Million SEK | -3.7% |
| 2021 Q1 | 3.01 Million SEK | -29.55% |
| 2021 FY | 3.34 Million SEK | -21.86% |
| 2021 Q4 | 3.34 Million SEK | -32.26% |
| 2021 Q3 | 4.93 Million SEK | -39.74% |
| 2021 Q2 | 8.18 Million SEK | 171.7% |
| 2020 Q2 | 3.59 Million SEK | 67.33% |
| 2020 Q3 | 5.44 Million SEK | 51.36% |
| 2020 Q4 | 4.27 Million SEK | -21.4% |
| 2020 Q1 | 2.14 Million SEK | 69.88% |
| 2020 FY | 4.27 Million SEK | 238.18% |
| 2019 FY | 1.26 Million SEK | 317.49% |
| 2019 Q2 | 1.01 Million SEK | -6.38% |
| 2019 Q4 | 1.26 Million SEK | 26.12% |
| 2019 Q3 | 1 Million SEK | -0.99% |
| 2019 Q1 | 1.08 Million SEK | 257.1% |
| 2018 Q3 | 776 Thousand SEK | -71.45% |
| 2018 Q4 | 303 Thousand SEK | -60.95% |
| 2018 FY | 303 Thousand SEK | -50.57% |
| 2018 Q2 | 2.71 Million SEK | 1598.75% |
| 2018 Q1 | 160 Thousand SEK | -73.9% |
| 2017 Q4 | 613 Thousand SEK | 0.0% |
| 2017 FY | 613 Thousand SEK | -83.15% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | 3.63 Million SEK | 2479.43% |
| 2015 FY | 141 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 219587.179% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | 398 Thousand SEK | -975.377% |
| AcouSort AB (publ) | 2.08 Million SEK | -105.769% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 82.204% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 87.851% |
| NextCell Pharma AB | 545.23 Thousand SEK | -684.98% |
| Amniotics AB (publ) | 534 Thousand SEK | -701.498% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -6.098% |
| Simris Alg AB (publ) | 1.09 Million SEK | -292.301% |
| Active Biotech AB (publ) | -2500.00 SEK | 171300.0% |
| Alzinova AB (publ) | -3.27 Million SEK | 230.567% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -213999900.0% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 79.048% |
| Camurus AB (publ) | 100.95 Million SEK | 95.76% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | -1.79 Million SEK | 337.91% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 1057.524% |
| Genovis AB (publ.) | 14.9 Million SEK | 71.285% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 288121.534% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Intervacc AB (publ) | 10.48 Million SEK | 59.172% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 363.223% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 595.945% |
| Saniona AB (publ) | 1.00 SEK | -427999900.0% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -427999900.0% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 1432.731% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 95.995% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 90.224% |
| Ziccum AB (publ) | -4.18 Million SEK | 202.172% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 159.978% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 210.967% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -427900.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 52.801% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -35.873% |
| Biovica International AB (publ) | 2.19 Million SEK | -94.634% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -511.429% |
| 2cureX AB (publ) | -1000.00 SEK | 428100.0% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 56.291% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 186.833% |
| Nanologica AB (publ) | 2.97 Million SEK | -43.962% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 63.864% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -76.495% |
| Pila Pharma AB (publ) | 1.00 SEK | -427999900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -316.342% |